Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905098 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL4329512 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL7718097 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL8746346 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL5579185 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL4329518 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL16718910 | 0.99 | MEN1 (0.76) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL16718912 | 0.99 | MEN1 (0.76) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL10699234 | 0.96 | MEN1 (0.84) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL29926784 | 0.96 | MEN1 (0.84) | MEN1KMT2ALTB4R2ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105899485-A | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids | 尊严科学有限公司 | 2016-08-24 | — | — | CN | claimed |
| WO-2022102788-A1 | COMPOSITION FOR ENHANCING ADRENOMEDULLIN GENE EXPRESSION | ハウスウェルネスフーズ株式会社 | 2022-05-19 | — | — | WO | disclosed |
| US-10197498-B2 | Compositions and methods for measurement of analytes | NORTHEASTERN UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| CN-109232278-A | The pharmaceutically acceptable salt of how unsaturated hydroxy fatty acid | DS生物制药有限公司 | 2019-01-18 | — | — | CN | disclosed |
| US-20160274030-A1 | COMPOSITIONS AND METHODS FOR MEASUREMENT OF ANALYTES | NORTHEASTERN UNIVERSITY (US) | 2016-09-22 | — | — | US | disclosed |
| CN-105899485-A | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids | 尊严科学有限公司 | 2016-08-24 | — | — | CN | disclosed |
| WO-2015061371-A1 | COMPOSITIONS AND METHODS FOR MEASUREMENT OF ANALYTES | NORTHEASTERN UNIVERSITY (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20070122865-A1 | Enzymes and enzymic processes | NANOBIODESIGN LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-6894059-B1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. (BE) | 2005-05-17 | — | — | US | disclosed |
| EP-1165533-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB SA (BE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1414950-A2 | CHIMERIC PROTEINS COMPRISING A HAEM DOMAIN OF A MAMMALIAN OR PLANT CYTOCHROME P450 AND A SCAFFOLD-REDUCTASE DOMAIN FROM P450 BM3 OF BACILLUS MEGATERIUM AND USES THEREOF | NanoBioDesign Limited (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2004-03-11 | — | — | US | disclosed |
| US-6686502-B1 | N-HYDROXYL-N-(3-BUTYNYL)-UREA CHEMICAL INTERMEDIATE FOR PIPERIDINE OR PIPERAZINE DERIVATIVES | UCB S.A. (BE) | 2004-02-03 | — | — | US | disclosed |
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2003-11-27 | — | — | US | disclosed |
| WO-2003014341-A2 | CHIMERIC PROTEINS COMPRISING A HAEM DOMAIN OF A MAMMALIAN OR PLANT CYTOCHROME P450 AND A SCAFFOLD-REDUCTASE DOMAIN FROM P450 BM3 OF BACILLUS MEGATERIUM AND USES THEREOF | NANOBIODESIGN LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
| CN-1387503-A | Hydroxyeicosatetraenoate salts, composition and method of use in treating dry eye disorders | ALCON UNIVERSAL LTD (CH) | 2002-12-25 | — | — | CN | disclosed |
| CN-1387505-A | Compositions contg. hydroxyeicosatetraenoic acid derivs, and methods of use in treating dry eye disorders | ALCON UNIVERSAL LTD (CH) | 2002-12-25 | — | — | CN | disclosed |
| US-6451801-B1 | 1,4-SUBSTITUTED PIPERIDINES AND PIPERAZINES | UCB, S.A. (BE) | 2002-09-17 | — | — | US | disclosed |
| EP-1165533-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058295-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | MEN1 2857/4885KMT2A 2264/4885LTB4R2 6/4885 |
| US-20070122865-A1 | Enzymes and enzymic processes | BLVRB, CYP4F3, POR | MEN1 3080/4885KMT2A 4529/4885LTB4R2 2921/4885 |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | MEN1 2857/4885KMT2A 2264/4885LTB4R2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.